Scott Capital Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$238K Sell
200
-70
-26% -$82.6K 0.03% 68
2026
Q2
$324K Hold
270
– – 0.05% 52
2026
Q1
$254K Hold
270
– – 0.05% 53
2025
Q4
$290K Sell
270
-552
-67% -$528K 0.06% 47
2025
Q3
$695K Buy
822
+51
+7% +$38K 0.16% 35
2025
Q2
$607K Buy
771
+76
+11% +$59.1K 0.16% 35
2025
Q1
$574K Buy
695
+12
+2% +$10K 0.17% 33
2024
Q4
$545K Sell
683
-55
-7% -$45.5K 0.16% 33
2024
Q3
$654K Buy
738
+17
+2% +$15.3K 0.19% 31
2024
Q2
$672K Buy
721
+70
+11% +$56K 0.2% 30
2024
Q1
$493K Buy
651
+151
+30% +$107K 0.15% 36
2023
Q4
$291K Buy
500
+65
+15% +$37.9K 0.1% 41
2023
Q3
$268K Buy
+435
New +$224K 0.11% 40

Other funds holding LLY

Scott Capital Advisors's LLY Position: Q3 2026 in Review

Scott Capital Advisors reduced its Eli Lilly (LLY) stake by 26% in Q3 2026, selling an estimated $82.6K and leaving 200 shares worth $238K. The position accounts for 0.03% of the portfolio, ranked #68.

Scott Capital Advisors first reported a position in LLY in Q3 2023 and has held it in 13 quarters since. The position peaked at $695K in Q3 2025. 2,091 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Scott Capital Advisors held 200 shares of Eli Lilly worth $238K as of Q3 2026.
  • Scott Capital Advisors sold 70 Eli Lilly shares in Q3 2026, an estimated $82.6K.
  • Eli Lilly made up 0.03% of Scott Capital Advisors's portfolio in Q3 2026, its #68 holding.
  • Scott Capital Advisors first reported a position in Eli Lilly in Q3 2023 and has held it in 13 quarters since.
  • Scott Capital Advisors's Eli Lilly position peaked at $695K in Q3 2025.
  • 2,091 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Scott Capital Advisors's 13F filing for Q3 2026, filed 13 Oct 2026.